Odyssey Therapeutics Files for U.S. IPO as Drug Developer
Odyssey Therapeutics’ drug developer IPO plans reflect a renewed push into public markets amid biotech investor demand, with focus on autoimmune and
Boehringer Ingelheim Secures U.S. Approval for Groundbreaking Lung Cancer Drug,
Boehringer Ingelheim has received approval from U.S. regulatory authorities for its new drug aimed at treating a difficult form of lung cancer. This authorization marks a significant milestone for the…